Corebridge Financial Inc. Has $4.99 Million Position in The Clorox Company (NYSE:CLX)

Corebridge Financial Inc. cut its holdings in shares of The Clorox Company (NYSE:CLX) by 4.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,738 shares of the company’s stock after selling 1,478 shares during the period. Corebridge Financial Inc.’s holdings in Clorox were worth $4,992,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Ilex Capital Partners UK LLP lifted its holdings in shares of Clorox by 512.7% during the third quarter. Ilex Capital Partners UK LLP now owns 542,110 shares of the company’s stock worth $88,315,000 after purchasing an additional 453,624 shares during the period. Amundi lifted its holdings in Clorox by 42.6% during the 4th quarter. Amundi now owns 1,032,283 shares of the company’s stock worth $165,816,000 after buying an additional 308,234 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Clorox by 302.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 353,367 shares of the company’s stock valued at $57,390,000 after buying an additional 265,455 shares during the last quarter. State Street Corp increased its stake in shares of Clorox by 3.1% in the third quarter. State Street Corp now owns 8,182,109 shares of the company’s stock valued at $1,332,947,000 after buying an additional 245,525 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Clorox during the fourth quarter worth about $37,935,000. 78.53% of the stock is owned by institutional investors.

Clorox Price Performance

Shares of NYSE:CLX opened at $146.18 on Friday. The Clorox Company has a twelve month low of $127.60 and a twelve month high of $171.37. The stock’s 50 day moving average is $151.34 and its 200-day moving average is $159.03. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52. The firm has a market capitalization of $18.01 billion, a price-to-earnings ratio of 39.94, a PEG ratio of 2.62 and a beta of 0.45.

Clorox (NYSE:CLX) last released its quarterly earnings data on Monday, February 3rd. The company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.16. Clorox had a net margin of 6.38% and a return on equity of 316.87%. During the same quarter in the prior year, the business earned $2.16 EPS. Sell-side analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Wednesday, April 23rd will be issued a dividend of $1.22 per share. This represents a $4.88 dividend on an annualized basis and a yield of 3.34%. The ex-dividend date is Wednesday, April 23rd. Clorox’s dividend payout ratio is currently 133.33%.

Analyst Ratings Changes

CLX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. increased their target price on shares of Clorox from $171.00 to $173.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. StockNews.com downgraded shares of Clorox from a “buy” rating to a “hold” rating in a research note on Sunday, January 5th. Barclays cut their price target on shares of Clorox from $140.00 to $139.00 and set an “underweight” rating on the stock in a research report on Thursday. DA Davidson decreased their price target on Clorox from $171.00 to $169.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $150.00 price objective on shares of Clorox in a research note on Thursday, January 30th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $159.50.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.